Antiemetics: Technologies and Global Markets
REPORT SCOPE
The report details the antiemetic drug market. The analysis highlights current and future market potential for antiemetic drug and presents a detailed review of pipeline drugs, blockbuster drugs, and challenges to market growth. The report also examines disease burden, regulatory environment, novel technologies, and market projections to 2023. Antiemetic drug market drivers, trends and potential regional market opportunities are also covered in this report.
The report details market shares of antiemetic drug class (5-HT3 receptor antagonists, dopamine antagonists, steroid-corticosteroids, benzodiazepines, NK1 receptor antagonist, antihistamines, cannabinoids, and anticholinergic) and geographic market segmentation of overall market; global market share by applications, with special emphasis on developed and underdeveloped geographic regions. For market estimates, data has been provided for 2017, as base year, 2018 and forecast for 2023.
REPORT INCLUDES
The report details the antiemetic drug market. The analysis highlights current and future market potential for antiemetic drug and presents a detailed review of pipeline drugs, blockbuster drugs, and challenges to market growth. The report also examines disease burden, regulatory environment, novel technologies, and market projections to 2023. Antiemetic drug market drivers, trends and potential regional market opportunities are also covered in this report.
The report details market shares of antiemetic drug class (5-HT3 receptor antagonists, dopamine antagonists, steroid-corticosteroids, benzodiazepines, NK1 receptor antagonist, antihistamines, cannabinoids, and anticholinergic) and geographic market segmentation of overall market; global market share by applications, with special emphasis on developed and underdeveloped geographic regions. For market estimates, data has been provided for 2017, as base year, 2018 and forecast for 2023.
REPORT INCLUDES
- 21 data tables and 15 additional tables
- Country specific data and analysis for United States, Canada, Mexico, France, Germany, UK, China, India, Japan, and Middle East and Africa
- An overview about current and future market potential for antiemetic drugs with special focus on competitive environment, pipeline drugs and blockbuster drugs
- Coverage of disease burden, regulatory environment, and novel technologies in the antiemetic drugs market
- Detailed description about vestibular disorder and increasing demand of innovative technology for treatment
- Exploration of the causes of emesis, usage of antiemetics and the types of products available to treat nausea and vomiting by each application segment
- Information about the launching of new drugs in each antiemetic drug class such as 5 HT3 receptor antagonists, dopamine antagonists, NK1 receptor antagonist, and so forth
- Detailed company profiles of major players in the market, including Abbott Laboratories, Daiichi Sankyo Company, Ltd., Merck & Co., Novartis AG, Sanofi Aventis and Teva Pharmaceutical Industries Ltd.
CHAPTER 1 INTRODUCTION
Antiemetic Technologies
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 OVERVIEW
Introduction
Causes of Nausea and Vomiting
Gastrointestinal Obstruction/Infection/Inflammation
Drug-Induced Nausea and Vomiting
Pregnancy-Induced Nausea and Vomiting
Post-operative Nausea and Vomiting
Vestibular Disorder
Pathophysiology of Nausea and Vomiting
Gastrointestinal Tract
Chemoreceptor Trigger Zone
Vestibular Apparatus
Cerebral Cortex
CHAPTER 4 MARKET AND TECHNOLOGY BACKGROUND
Drivers
Global Increase in Number of Pregnancies and Burden of Underlying Disease Conditions
Increasing in Research Grants and Funding
Growing Research Activity in Innovative Antiemetic Drug Therapy
Use of Novel Drug Deliveries to Treat Nausea and Vomiting
Restraints
Lack of Animal Models to Prove Efficacy of Antiemetics
Pricing Pressure Experienced by Innovators
Availability of Alternative Treatments
Opportunities
Disease Burden and Increasing Number of Pregnancies in Europe and Asia-Pacific
Vestibular Disorders
Emergence of Advanced Therapies
Patent Expiry
CHAPTER 5 MARKET BREAKDOWN BY DRUG CLASS
Introduction
Global Antiemetic Drugs Market
5-HT3 Receptor Antagonists
NK1 Receptor Antagonist
Dopamine Antagonists
Antihistamines (H1 Receptor Antagonists)
Cannabinoids
Benzodiazepines
Corticosteroids
Anticholinergics
CHAPTER 6 MARKET BREAKDOWN BY APPLICATION
Overview
Market Size and Forecast
Chemotherapy-Induced Nausea and Vomiting
Introduction
Market Size and Forecast
Key CINV Market Takeaways
Gastroenteritis
Market Size and Forecast
Nausea and Vomiting of Pregnancy (NVP)
Market Size and Forecast
Post-Operative Nausea and Vomiting
Market Size and Forecast
CHAPTER 7 MARKET BREAKDOWN BY REGION
Overview
Market Size and Forecast
North America
Market Size and Forecast
United States
Canada
Mexico
Europe
Market Size and Forecast
United Kingdom
Germany
Asia-Pacific
Market Size and Forecast
Middle East and Africa
South America
CHAPTER 8 PATENT REVIEW/NEW DEVELOPMENTS
Introduction
CHAPTER 9 PIPELINE ANALYSIS
Introduction
NK1 Receptor Antagonists
CHAPTER 10 REGULATORY LANDSCAPE
Introduction
Regional Regulatory Landscape
North America
Europe
Asia-Pacific
CHAPTER 11 COMPANY PROFILES
ABBOTT LABORATORIES
Overview
Financial Information
Products and Services
Development and Strategies
ASTELLAS PHARMA INC.
Overview
Financial Information
Products and Services
Development and Strategies
APHIOS CORP.
Overview
AUROBINDO PHARMA
Overview
Financial Information
Products and Services
DAIICHI SANKYO COMPANY LTD.
Overview
Financial Information
Product and Services
Development and Strategies
EISAI CO., INC.
Overview
Financial Information
Products and Services
GLAXOSMITHKLINE PLC
Overview
Financial Information
Products and Services
HELSINN HEALTHCARE SA
Overview
Products and Services
Key Developments and Strategies
HERON THERAPEUTICS, INC.
Overview
Financials
Products and Services
IPCA LABORATORIES, LTD.
Overview
KYOWA HAKKO KIRIN PHARMA, INC.
Overview
Financials
MERCK & CO., INC.
Overview
Financial Information
Products and Services
NOVARTIS AG
Overview
Financial Information
F. HOFFMANN-LA ROCHE AG
Overview
Financial Information
Products and Services
SANOFI AVENTIS
Overview
Financial Information
Products and Services
TESARO, INC.
Overview
Financial Information
Products and Services
Development and strategies
TEVA PHARMACEUTICAL INDUSTRIES LTD.
Overview
Financial Information
Product and Services
Development and Strategies
CHAPTER 12 APPENDIX: ABBREVIATIONS
Antiemetic Technologies
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 OVERVIEW
Introduction
Causes of Nausea and Vomiting
Gastrointestinal Obstruction/Infection/Inflammation
Drug-Induced Nausea and Vomiting
Pregnancy-Induced Nausea and Vomiting
Post-operative Nausea and Vomiting
Vestibular Disorder
Pathophysiology of Nausea and Vomiting
Gastrointestinal Tract
Chemoreceptor Trigger Zone
Vestibular Apparatus
Cerebral Cortex
CHAPTER 4 MARKET AND TECHNOLOGY BACKGROUND
Drivers
Global Increase in Number of Pregnancies and Burden of Underlying Disease Conditions
Increasing in Research Grants and Funding
Growing Research Activity in Innovative Antiemetic Drug Therapy
Use of Novel Drug Deliveries to Treat Nausea and Vomiting
Restraints
Lack of Animal Models to Prove Efficacy of Antiemetics
Pricing Pressure Experienced by Innovators
Availability of Alternative Treatments
Opportunities
Disease Burden and Increasing Number of Pregnancies in Europe and Asia-Pacific
Vestibular Disorders
Emergence of Advanced Therapies
Patent Expiry
CHAPTER 5 MARKET BREAKDOWN BY DRUG CLASS
Introduction
Global Antiemetic Drugs Market
5-HT3 Receptor Antagonists
NK1 Receptor Antagonist
Dopamine Antagonists
Antihistamines (H1 Receptor Antagonists)
Cannabinoids
Benzodiazepines
Corticosteroids
Anticholinergics
CHAPTER 6 MARKET BREAKDOWN BY APPLICATION
Overview
Market Size and Forecast
Chemotherapy-Induced Nausea and Vomiting
Introduction
Market Size and Forecast
Key CINV Market Takeaways
Gastroenteritis
Market Size and Forecast
Nausea and Vomiting of Pregnancy (NVP)
Market Size and Forecast
Post-Operative Nausea and Vomiting
Market Size and Forecast
CHAPTER 7 MARKET BREAKDOWN BY REGION
Overview
Market Size and Forecast
North America
Market Size and Forecast
United States
Canada
Mexico
Europe
Market Size and Forecast
United Kingdom
Germany
Asia-Pacific
Market Size and Forecast
Middle East and Africa
South America
CHAPTER 8 PATENT REVIEW/NEW DEVELOPMENTS
Introduction
CHAPTER 9 PIPELINE ANALYSIS
Introduction
NK1 Receptor Antagonists
CHAPTER 10 REGULATORY LANDSCAPE
Introduction
Regional Regulatory Landscape
North America
Europe
Asia-Pacific
CHAPTER 11 COMPANY PROFILES
ABBOTT LABORATORIES
Overview
Financial Information
Products and Services
Development and Strategies
ASTELLAS PHARMA INC.
Overview
Financial Information
Products and Services
Development and Strategies
APHIOS CORP.
Overview
AUROBINDO PHARMA
Overview
Financial Information
Products and Services
DAIICHI SANKYO COMPANY LTD.
Overview
Financial Information
Product and Services
Development and Strategies
EISAI CO., INC.
Overview
Financial Information
Products and Services
GLAXOSMITHKLINE PLC
Overview
Financial Information
Products and Services
HELSINN HEALTHCARE SA
Overview
Products and Services
Key Developments and Strategies
HERON THERAPEUTICS, INC.
Overview
Financials
Products and Services
IPCA LABORATORIES, LTD.
Overview
KYOWA HAKKO KIRIN PHARMA, INC.
Overview
Financials
MERCK & CO., INC.
Overview
Financial Information
Products and Services
NOVARTIS AG
Overview
Financial Information
F. HOFFMANN-LA ROCHE AG
Overview
Financial Information
Products and Services
SANOFI AVENTIS
Overview
Financial Information
Products and Services
TESARO, INC.
Overview
Financial Information
Products and Services
Development and strategies
TEVA PHARMACEUTICAL INDUSTRIES LTD.
Overview
Financial Information
Product and Services
Development and Strategies
CHAPTER 12 APPENDIX: ABBREVIATIONS
LIST OF TABLES
Summary Table A: Global Antiemetic Drugs Market, by Drug Class, Through 2023
Summary Table B: Global Antiemetic Drugs Market, by Application, Through 2023
Table 1: Emetic Potency of Chemotherapeutic Agents
Table 2: Vomiting as Adverse Effect at Therapeutic Dosage
Table 3: Ondansetron Patent Expiration
Table 4: Aloxi Patent Expiration
Table 5: List of FDA approved Antiemetic Drugs and Indications
Table 6: Global Antiemetic Drugs Market, by Drug Class, Through 2023
Table 7: 5-HT3 Receptor Drugs
Table 8: FDA Approved Dopamine Antagonists
Table 9: Global Antiemetic Drugs Market, by Application, Through 2023
Table 10: Global Antiemetic Drugs Market, by Region, Through 2023
Table 11: Antiemetic Drug Patents
Table 12: Antiemetic Drug Candidates
Table 13: FDA Approved Drugs
Table 14: List of Antiemetic Drugs Approved in Japan
Table 15: Abbott Laboratories: Net Revenue, 2015-2017
Table 16: Abbott Laboratories: Net Revenue, by Segment, 2017
Table 17: Abbott Laboratories: Marketed Products, 2016
Table 18: Astellas Pharma Inc.: Net Revenue, 2015-2017
Table 19: Astellas Pharma Inc.: Marketed Products, 2016
Table 20: Aurobindo Pharma Ltd.: Net Revenue, 2015-2017
Table 21: Daiichi Sankyo Company Ltd.: Net Revenue, 2015-2017
Table 22: Eisai Co., Inc.: Net Revenue, by Region, 2014-2016
Table 23: Eisai Co., Inc.: Oncology Product Sales, 2014-2016
Table 24: GlaxoSmithKline PLC: Net Revenue, 2014-2016
Table 25: Heron Therapeutics Inc.: Net Revenue, 2016-2017
Table 26: Kyowa Hakko Kirin Pharma Inc.: Net Revenue, 2013-2017
Table 27: Merck & Co. Inc.: Net Revenue, 2014-2016
Table 28: Novartis AG: Net Revenue, 2014-2016
Table 29: F. Hoffmann-La Roche Ltd.: Net Revenue, by Segment, Through 2017
Table 30: Sanofi: Net Revenue, 2014-2016
Table 31: Teva Pharmaceutical Industries Ltd.: Net Revenue, 2015-2017
Table 32: Teva Pharmaceutical Industries Ltd.: Net Revenue, by Segments, 2015-2017
Table 33: Teva Pharmaceutical Industries Ltd: Products and Services
Table 34: Abbreviations
Summary Table A: Global Antiemetic Drugs Market, by Drug Class, Through 2023
Summary Table B: Global Antiemetic Drugs Market, by Application, Through 2023
Table 1: Emetic Potency of Chemotherapeutic Agents
Table 2: Vomiting as Adverse Effect at Therapeutic Dosage
Table 3: Ondansetron Patent Expiration
Table 4: Aloxi Patent Expiration
Table 5: List of FDA approved Antiemetic Drugs and Indications
Table 6: Global Antiemetic Drugs Market, by Drug Class, Through 2023
Table 7: 5-HT3 Receptor Drugs
Table 8: FDA Approved Dopamine Antagonists
Table 9: Global Antiemetic Drugs Market, by Application, Through 2023
Table 10: Global Antiemetic Drugs Market, by Region, Through 2023
Table 11: Antiemetic Drug Patents
Table 12: Antiemetic Drug Candidates
Table 13: FDA Approved Drugs
Table 14: List of Antiemetic Drugs Approved in Japan
Table 15: Abbott Laboratories: Net Revenue, 2015-2017
Table 16: Abbott Laboratories: Net Revenue, by Segment, 2017
Table 17: Abbott Laboratories: Marketed Products, 2016
Table 18: Astellas Pharma Inc.: Net Revenue, 2015-2017
Table 19: Astellas Pharma Inc.: Marketed Products, 2016
Table 20: Aurobindo Pharma Ltd.: Net Revenue, 2015-2017
Table 21: Daiichi Sankyo Company Ltd.: Net Revenue, 2015-2017
Table 22: Eisai Co., Inc.: Net Revenue, by Region, 2014-2016
Table 23: Eisai Co., Inc.: Oncology Product Sales, 2014-2016
Table 24: GlaxoSmithKline PLC: Net Revenue, 2014-2016
Table 25: Heron Therapeutics Inc.: Net Revenue, 2016-2017
Table 26: Kyowa Hakko Kirin Pharma Inc.: Net Revenue, 2013-2017
Table 27: Merck & Co. Inc.: Net Revenue, 2014-2016
Table 28: Novartis AG: Net Revenue, 2014-2016
Table 29: F. Hoffmann-La Roche Ltd.: Net Revenue, by Segment, Through 2017
Table 30: Sanofi: Net Revenue, 2014-2016
Table 31: Teva Pharmaceutical Industries Ltd.: Net Revenue, 2015-2017
Table 32: Teva Pharmaceutical Industries Ltd.: Net Revenue, by Segments, 2015-2017
Table 33: Teva Pharmaceutical Industries Ltd: Products and Services
Table 34: Abbreviations
LIST OF FIGURES
Summary Figure A: Global Antiemetic Drugs Market, by Drug Class, 2017-2023
Summary Figure B: Global Antiemetic Drugs Market, by Application, 2017-2023
Figure 1: Mechanism of Chemotherapy-Induced Nausea and Vomiting
Figure 2: Pathophysiology of Nausea and Vomiting
Figure 3: Pathophysiology of Emesis
Figure 4: Global Antiemetic Drugs Market, by Drug Class, 2017-2023
Figure 5: Global Market Share of Antiemetics, by Drug Class, 2017
Figure 6: Global 5-HT3 Receptor Market, 2017-2023
Figure 7: Global NK1 Receptor Antagonist Market, 2017-2023
Figure 8: Global Dopamine Receptor Market, 2017-2023
Figure 9: Global Antihistamines Receptor Antagonist Market, 2017-2023
Figure 10: Global Cannabinoids Market, 2017-2023
Figure 11: Global Benzodiazepines Market, 2017-2023
Figure 12: Global Corticosteroid Market, 2017-2023
Figure 13: Global Anticholinergic Drugs Market, 2017-2023
Figure 14: Global Market Share for Antiemetics Drug, by Application, 2017
Figure 15: Global CINV Drugs Market, 2017-2023
Figure 16: Global Gastroenteritis Antiemetic Drug Market, 2017-2023
Figure 17: Global NVP Antiemetic Drug Market, 2017-2023
Figure 18: Global PONV Antiemetic Drugs Market, 2017-2023
Figure 19: Global Antiemetic Drugs Market, by Region, 2017-2023
Figure 20: North America Antiemetic Drugs Market, 2017-2023
Figure 21: North America Antiemetic Drugs Market, by Application, 2017-2023
Figure 22: Europe Antiemetic Drugs Market, 2017-2023
Figure 23: Europe Antiemetic Drugs Market, by Application, 2017-2023
Figure 24: Asia-Pacific Antiemetic Drugs Market, 2017-2023
Figure 25: Asia-Pacific Antiemetic Drugs Market, by Application, 2017-2023
Figure 26: Middle East and Africa Antiemetic Drugs Market, 2017-2023
Figure 27: South America Antiemetic Drugs Market, 2017-2023
Figure 28: Abbott Laboratories: Revenue Share, by Segment, 2017
Figure 29: Astellas Pharma Inc.: Revenue Share, by Segment, 2017
Figure 30: Aurobindo Pharma Ltd.: Revenue Share, by Segment, 2017
Figure 31: Daiichi Sankyo Company Ltd.: Revenue Share, by Business Segment, 2016
Figure 32: GlaxoSmithKline PLC: Revenue Share, by Business Segment, 2016
Figure 33: GlaxoSmithKline PLC: Revenue Share, by Region, 2016
Figure 34: Merck & Co. Inc.: Revenue Share, by Business Segment, 2016
Figure 35: Merck & Co. Inc.: Revenue Share, by Region, 2016
Figure 36: Novartis AG: Revenue Share, by Region, 2016
Figure 37: Novartis AG: Revenue Share, by Business Segment, 2016
Figure 38: F. Hoffmann-La Roche Ltd.: Pharmaceuticals Revenue Share, by Business Segment, 2016
Figure 39: Sanofi: Revenue Share, by Region, 2016
Figure 40: Sanofi: Revenue Share, by Business Segment, 2016
Figure 41: Sanofi: Revenue Share, by Pharmaceuticals Segment, 2017
Figure 42: Tesaro, Inc.: Net Revenue, 2015-2017
Figure 43: Teva Pharmaceutical Industries Ltd.: Generic Medicines Segment Revenue Share, by Region, 2017
COMPANIES MENTIONED
ABBOTT LABORATORIES
APHIOS CORP.
ASTELLAS PHARMA INC.
AUROBINDO PHARMA
DAIICHI SANKYO COMPANY LTD.
EISAI CO., INC.
F. Hoffmann-La Roche AG
GLAXOSMITHKLINE PLC
HELSINN HEALTHCARE SA
HERON THERAPEUTICS, INC.
IPCA LABORATORIES, LTD.
KYOWA HAKKO KIRIN PHARMA, INC.
MERCK & CO., INC.
NOVARTIS AG
SANOFI AVENTIS
TESARO, INC.
TEVA PHARMACEUTICAL INDUSTRIES LTD.
Summary Figure A: Global Antiemetic Drugs Market, by Drug Class, 2017-2023
Summary Figure B: Global Antiemetic Drugs Market, by Application, 2017-2023
Figure 1: Mechanism of Chemotherapy-Induced Nausea and Vomiting
Figure 2: Pathophysiology of Nausea and Vomiting
Figure 3: Pathophysiology of Emesis
Figure 4: Global Antiemetic Drugs Market, by Drug Class, 2017-2023
Figure 5: Global Market Share of Antiemetics, by Drug Class, 2017
Figure 6: Global 5-HT3 Receptor Market, 2017-2023
Figure 7: Global NK1 Receptor Antagonist Market, 2017-2023
Figure 8: Global Dopamine Receptor Market, 2017-2023
Figure 9: Global Antihistamines Receptor Antagonist Market, 2017-2023
Figure 10: Global Cannabinoids Market, 2017-2023
Figure 11: Global Benzodiazepines Market, 2017-2023
Figure 12: Global Corticosteroid Market, 2017-2023
Figure 13: Global Anticholinergic Drugs Market, 2017-2023
Figure 14: Global Market Share for Antiemetics Drug, by Application, 2017
Figure 15: Global CINV Drugs Market, 2017-2023
Figure 16: Global Gastroenteritis Antiemetic Drug Market, 2017-2023
Figure 17: Global NVP Antiemetic Drug Market, 2017-2023
Figure 18: Global PONV Antiemetic Drugs Market, 2017-2023
Figure 19: Global Antiemetic Drugs Market, by Region, 2017-2023
Figure 20: North America Antiemetic Drugs Market, 2017-2023
Figure 21: North America Antiemetic Drugs Market, by Application, 2017-2023
Figure 22: Europe Antiemetic Drugs Market, 2017-2023
Figure 23: Europe Antiemetic Drugs Market, by Application, 2017-2023
Figure 24: Asia-Pacific Antiemetic Drugs Market, 2017-2023
Figure 25: Asia-Pacific Antiemetic Drugs Market, by Application, 2017-2023
Figure 26: Middle East and Africa Antiemetic Drugs Market, 2017-2023
Figure 27: South America Antiemetic Drugs Market, 2017-2023
Figure 28: Abbott Laboratories: Revenue Share, by Segment, 2017
Figure 29: Astellas Pharma Inc.: Revenue Share, by Segment, 2017
Figure 30: Aurobindo Pharma Ltd.: Revenue Share, by Segment, 2017
Figure 31: Daiichi Sankyo Company Ltd.: Revenue Share, by Business Segment, 2016
Figure 32: GlaxoSmithKline PLC: Revenue Share, by Business Segment, 2016
Figure 33: GlaxoSmithKline PLC: Revenue Share, by Region, 2016
Figure 34: Merck & Co. Inc.: Revenue Share, by Business Segment, 2016
Figure 35: Merck & Co. Inc.: Revenue Share, by Region, 2016
Figure 36: Novartis AG: Revenue Share, by Region, 2016
Figure 37: Novartis AG: Revenue Share, by Business Segment, 2016
Figure 38: F. Hoffmann-La Roche Ltd.: Pharmaceuticals Revenue Share, by Business Segment, 2016
Figure 39: Sanofi: Revenue Share, by Region, 2016
Figure 40: Sanofi: Revenue Share, by Business Segment, 2016
Figure 41: Sanofi: Revenue Share, by Pharmaceuticals Segment, 2017
Figure 42: Tesaro, Inc.: Net Revenue, 2015-2017
Figure 43: Teva Pharmaceutical Industries Ltd.: Generic Medicines Segment Revenue Share, by Region, 2017
COMPANIES MENTIONED
ABBOTT LABORATORIES
APHIOS CORP.
ASTELLAS PHARMA INC.
AUROBINDO PHARMA
DAIICHI SANKYO COMPANY LTD.
EISAI CO., INC.
F. Hoffmann-La Roche AG
GLAXOSMITHKLINE PLC
HELSINN HEALTHCARE SA
HERON THERAPEUTICS, INC.
IPCA LABORATORIES, LTD.
KYOWA HAKKO KIRIN PHARMA, INC.
MERCK & CO., INC.
NOVARTIS AG
SANOFI AVENTIS
TESARO, INC.
TEVA PHARMACEUTICAL INDUSTRIES LTD.
